SCHEMBL5409878

SCHEMBL5409878

O=S(=O)(Nc1nnc(-c2ccccc2)s1)c1ccc2ccccc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.67
HTT P42858 3/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
ALOX12 P18054 1/20 0.67
AKT1 P31749 1/20 0.62
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA5A P35218 2/20 0.57
CA5B Q9Y2D0 2/20 0.57
CA4 P22748 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.54
KDM1A O60341 2/20 0.53
PGR P06401 1/20 0.49
PFKFB3 Q16875 1/20 0.48
HSD11B1 P28845 1/20 0.48
ATM Q13315 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
USP2 O75604 1/20 0.47
USP8 P40818 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5830937 0.84 MEN1 (0.81) LMNAHTTMEN1KMT2AALOX12
SCHEMBL5401437 0.81 LMNA (0.71) LMNAHTTMEN1KMT2AALOX12
SCHEMBL5386848 0.81 LMNA (0.75) LMNAHTTMEN1KMT2AALOX12
SCHEMBL2177851 0.81 LMNA (0.75) LMNAHTTMEN1KMT2AALOX12
SCHEMBL634004 0.81 MEN1 (0.75) LMNAHTTMEN1KMT2AALOX12
SCHEMBL5406688 0.80 ALDH1A1 (0.67) LMNAHTTMEN1KMT2AAKT1
SCHEMBL634365 0.80 MEN1 (0.62) LMNAHTTMEN1KMT2AALOX12
SCHEMBL5401782 0.79 ALDH1A1 (0.65) LMNAHTTMEN1KMT2AAKT1
SCHEMBL2197860 0.77 MEN1 (0.70) LMNAHTTMEN1KMT2AALOX12
SCHEMBL5391633 0.77 MEN1 (0.58) LMNAHTTMEN1KMT2AALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 LMNA 2030/4885HTT 3347/4885MEN1 942/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 LMNA 1581/4885HTT 2479/4885MEN1 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.